Trial Profile
Reduced Intensity Matched Sibling Bone Marrow Transplantation for Sickle Cell Anemia in Patients 2-30 Years Old
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2022
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Fludarabine (Primary) ; Melphalan (Primary) ; Stem cell therapies
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- 12 Oct 2022 Status changed from active, no longer recruiting to completed.
- 04 Feb 2022 Planned End Date changed from 1 Nov 2022 to 1 Nov 2023.
- 03 Feb 2021 Planned End Date changed from 1 Nov 2020 to 1 Nov 2022.